Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer

Shingo Tamura, Hitoshi Kusaba, Naoki Kubo, Kayo Ijichi, Kenji Tsuchihashi, Masato Komoda, Keita Uchino, hiroshi ariyama, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Bevacizumab is a widely used agent for treatment for colorectal cancer. Though it relates to several adverse events, a few cases have been reported of drug-induced interstitial lung damage in bevacizumab-based chemotherapy for advanced colorectal cancer. In this study, we retrospectively reviewed a consecutive series of 72 patients with advanced colorectal cancer who received bevacizumab-based chemotherapy and identified five cases (6.9 %) who developed interstitial pneumonia (IP). The median age was 68 years, all five were male, and four of five patients were smokers. Three cases were asymptomatic, and they immediately recovered by withdrawal of chemotherapeutic drugs. On the other hand, two severe cases were required high-dose infusion of corticosteroid. It is suggested that early diagnosis of IP contributes to prevent exacerbation of the event and results in better outcomes. IP may have been associated with systemic chemotherapy, suggesting that a caution should be raised for pulmonary damage by bevacizumab-based chemotherapy.

元の言語英語
記事番号856
ジャーナルMedical Oncology
31
発行部数3
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Interstitial Lung Diseases
Colorectal Neoplasms
Drug Therapy
Lung
Pharmaceutical Preparations
Early Diagnosis
Adrenal Cortex Hormones
Bevacizumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

これを引用

Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer. / Tamura, Shingo; Kusaba, Hitoshi; Kubo, Naoki; Ijichi, Kayo; Tsuchihashi, Kenji; Komoda, Masato; Uchino, Keita; ariyama, hiroshi; Akashi, Koichi; Baba, Eishi.

:: Medical Oncology, 巻 31, 番号 3, 856, 01.01.2014.

研究成果: ジャーナルへの寄稿記事

@article{c9ac56d57cac47b682eec0e91e9f8867,
title = "Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer",
abstract = "Bevacizumab is a widely used agent for treatment for colorectal cancer. Though it relates to several adverse events, a few cases have been reported of drug-induced interstitial lung damage in bevacizumab-based chemotherapy for advanced colorectal cancer. In this study, we retrospectively reviewed a consecutive series of 72 patients with advanced colorectal cancer who received bevacizumab-based chemotherapy and identified five cases (6.9 {\%}) who developed interstitial pneumonia (IP). The median age was 68 years, all five were male, and four of five patients were smokers. Three cases were asymptomatic, and they immediately recovered by withdrawal of chemotherapeutic drugs. On the other hand, two severe cases were required high-dose infusion of corticosteroid. It is suggested that early diagnosis of IP contributes to prevent exacerbation of the event and results in better outcomes. IP may have been associated with systemic chemotherapy, suggesting that a caution should be raised for pulmonary damage by bevacizumab-based chemotherapy.",
author = "Shingo Tamura and Hitoshi Kusaba and Naoki Kubo and Kayo Ijichi and Kenji Tsuchihashi and Masato Komoda and Keita Uchino and hiroshi ariyama and Koichi Akashi and Eishi Baba",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12032-014-0856-0",
language = "English",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer

AU - Tamura, Shingo

AU - Kusaba, Hitoshi

AU - Kubo, Naoki

AU - Ijichi, Kayo

AU - Tsuchihashi, Kenji

AU - Komoda, Masato

AU - Uchino, Keita

AU - ariyama, hiroshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Bevacizumab is a widely used agent for treatment for colorectal cancer. Though it relates to several adverse events, a few cases have been reported of drug-induced interstitial lung damage in bevacizumab-based chemotherapy for advanced colorectal cancer. In this study, we retrospectively reviewed a consecutive series of 72 patients with advanced colorectal cancer who received bevacizumab-based chemotherapy and identified five cases (6.9 %) who developed interstitial pneumonia (IP). The median age was 68 years, all five were male, and four of five patients were smokers. Three cases were asymptomatic, and they immediately recovered by withdrawal of chemotherapeutic drugs. On the other hand, two severe cases were required high-dose infusion of corticosteroid. It is suggested that early diagnosis of IP contributes to prevent exacerbation of the event and results in better outcomes. IP may have been associated with systemic chemotherapy, suggesting that a caution should be raised for pulmonary damage by bevacizumab-based chemotherapy.

AB - Bevacizumab is a widely used agent for treatment for colorectal cancer. Though it relates to several adverse events, a few cases have been reported of drug-induced interstitial lung damage in bevacizumab-based chemotherapy for advanced colorectal cancer. In this study, we retrospectively reviewed a consecutive series of 72 patients with advanced colorectal cancer who received bevacizumab-based chemotherapy and identified five cases (6.9 %) who developed interstitial pneumonia (IP). The median age was 68 years, all five were male, and four of five patients were smokers. Three cases were asymptomatic, and they immediately recovered by withdrawal of chemotherapeutic drugs. On the other hand, two severe cases were required high-dose infusion of corticosteroid. It is suggested that early diagnosis of IP contributes to prevent exacerbation of the event and results in better outcomes. IP may have been associated with systemic chemotherapy, suggesting that a caution should be raised for pulmonary damage by bevacizumab-based chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84892936571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892936571&partnerID=8YFLogxK

U2 - 10.1007/s12032-014-0856-0

DO - 10.1007/s12032-014-0856-0

M3 - Article

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

M1 - 856

ER -